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We recently showed that macrophage-stimulating protein (MSP), a serum protein homologous to hepatocyte
growth factor, promotes ciliary motility by activating its receptor, RON, on the airway ciliated epithelium. To
investigate the functional involvement of MSP and RON in bronchiectasis, in which mucociliary clearance (MCC)
is impaired, first we examined RON expression on the bronchial ciliated epithelium of patients with bronchiectasis.
We confirmed RON expression at the apical surface of bronchial ciliated epithelium of patients with bronchiectasis
as well as those of normal human bronchus. Next, we examined whether MSP is present in sputum of patients with
bronchiectasis and normal control subjects. By Western blotting, we found that half of the MSP in sputum is
present as a biologically active a/b chain heterodimer (mature MSP). In addition, we found that the MSP
concentrations in sputum were significantly elevated in patients with bronchiectasis (n=8; 16?8+3?0 ng ml71)
compared with normal controls (n=9; 8?4+2?4 ng ml71; P50?05). In contrast, the dierence in concentrations of
serum MSP (pro-MSP) was not significant between the two groups. These results indicate that (i) MSP is supplied
to the airways and converted to a biologically active form, (ii) MSP is increased in patients with bronchiectasis
compared with normal controls. Taken together, our findings suggest that increased MSP may be involved in
compensation for impaired MCC in bronchiectasis.
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Bronchiectasis is a disease of mucus hypersecretion and
recurrent airway inflammation that causes destruction of
the ciliated epithelium and submucosa with elastic and
muscular tissue degeneration (1,2). It has been demon-
strated that mucociliary clearance (MCC) is impaired in the
airways of patients with bronchiectasis (3,4). Impaired
MCC may be due to abnormal mucociliary function,
abnormal load and rheology of mucus, or abnormal
interaction between cilia and mucus (5). The lungs of
patients with bronchiectasis are frequently colonized by
Haemophilus influenzae and Pseudomonas aeruginosa (6).
Soluble products Pseudomonas aeruginosa, such as pyocya-
nin and 1-hydroxyphenazine, were found to inhibit ciliary
beat frequency (CBF) of human respiratory cilia in vitro
and cause the reduction of tracheal mucus velocity in vivoReceived 31 January 2000 and accepted 8 March 2000.
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0954-6111/00/080784+07 $35?00/0(7,8). Thus, ciliary dysfunction may be involved in the
impairment of MCC in patients with bronchiectasis.
Recently, we have demonstrated that the receptor
tyrosine kinase RON is expressed on the airway ciliated
epithelium, and that its ligand macrophage-stimulating
protein (MSP) promotes ciliary motility in these cells by
activating RON (9). These findings suggest that MSP
functions as one regulatory factor of ciliary motility and
plays an important role in the airway mucociliary trans-
port. To date, however, the biological significance of MSP
in the airway mucociliary transport in vivo has not been
clarified.
MSP is an 80-kD serum protein that was originally found
to stimulate murine resident peritoneal macrophages to
make a chemotactic response to C5a (10). MSP belongs to a
family characterized by the presence of a highly conserved
triple disulphide loop structure (kringle domain). The
family includes prothrombin, plasminogen, urokinase and
hepatocyte growth factor, the latter of which shows high
homology to MSP (45% identity at the amino acid level)
(11–14). Proteins in this family are secreted as single-chain
precursors that acquire biological activity upon cleavage by
specific serine proteases. It has been shown that MSP is
synthesized by hepatocytes (11,13,15) and secreted as
biologically inactive pro-MSP, the single-chain precursor
of MSP, into the circulation. In addition, pro-MSP is# 2000 HARCOURT PUBLISHERS LTD
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dimer (mature MSP) by serine proteases such as enzymes of
the intrinsic coagulation cascade (16).
To explore the role of MSP and RON in bronchiectasis,
initially we investigated whether RON is expressed on the
bronchial ciliated epithelium of patients with bronchiecta-
sis. In addition, we investigated whether MSP is present in
induced sputum and measured the concentrations of MSP
in induced sputum of patients with bronchiectasis and
normal control subjects. In this paper, we show that RON
is expressed at the apical surface bronchial ciliated
epithelium of patients with bronchiectasis. Furthermore,
we show that half of the MSP in sputum is present as
biologically active mature MSP, and that MSP concentra-
tions in sputum are significantly increased in patients with
bronchiectasis compared with normal controls.
Methods
SUBJECTS
Seventeen subjects participated in the study after giving
informed consent. Eight were patients with bronchiectasis.
Nine were control subjects who had no history of
pulmonary diseases. The chest roentgenograms and pul-
monary function tests of nine controls were normal. The
study was approved by the Institutional Review Board of
Kumamoto University. Patients with bronchiectasis were
diagnosed by chest roentgenogram and computed tomo-
graphy. All cases of bronchiectasis occurred with post-
infectious causes and recurrent persistent infections. None
of them had immunoglobulin deficiency or Kartagener’s
syndrome. All subjects underwent clinical, hematological,
and chemical examinations in order to exclude acute
infectious exacerbations. Forced vital capacity (FVC) and
forced expiratory volume in 1 sec (FEV1) were measured by
a dry rollingseal spirometer (Chestac-65V, Chest Co.,
Tokyo, Japan). The clinical characteristics of these subjects
are shown in Table 1.
SPUTUM INDUCTION AND PROCESSING
Before collection of samples subjects were asked to rinse
their mouth, swallow water, and blow their nose to
minimize contamination with saliva and post-nasal drip.
Then inhalation of hypertonic saline (3%) was performed
using an ultrasonic nebulizer (NE-U11, Omron Co., Tokyo,
Japan). Inhalation of hypertonic saline was continued for
15–20 min until the sputum volume was over 1 ml. The
nebulizer generated particles with a mass diamter of 1–5 mm
and had an output of 1?5 ml min71. Subjects were
encouraged to cough throughout the procedure, and they
regularly interrupted inhalation of hypertonic saline in
order to expectorate sputum into a clean plastic dish.
The assessment of the quality of the obtained samples
was performed as described by Pin et al. (17). One thousand
microlitres of sputum was immediately cooled on ice and
combined with 950 ml of phosphate buered saline (PBS)
and 50 ml of 2 mM p-amidinophenyl methanesulphonylfluoride hydrochloride (APMSF) (Wako Pure Chemical,
Osaka, Japan). The samples were then homogenized and
centrifuged at 14 000 rpm at 48C for 20 min. The obtained
supernatants were frozen immediately at 7708C.
IMMUNOHISTOCHEMISTRY
Subsegmental bronchi (diameter: 3–6 mm) of normal
control and patients with bronchiectasis were obtained
from surgical and autopsy samples. Immediately after the
tissues were obtained, they were mounted in OCT 4583
embedding compound (Miles Inc, Elkhart, IN, U.S.A.) and
then frozen in liquid nitrogen. Serial cryostat sections (6-mm
thick) cut in a MICROM cryomicrotome were air dried,
and fixed in acetone for 10 min at 48C. After washing with
PBS three times, cryostat sections were treated with 5 mM
orthoperiodic acid solution for 10 min to block endogenous
peroxidase activity as described (18). The sections were
stained with a rabbit polyclonal antibody against RON
(0?2–0?5 mg ml71) (Santa Cruz Biotechnology, Inc., CA,
U.S.A.) by the indirect immunoperoxidase method using
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
(Amersham International, Little Chalfont, U.K.). Perox-
idase activity was visualized using 3,3’-diaminobenzidine
(Dojindo, Kumamoto, Japan) as a substrate. To confirm
the specific reactivity of anti-RON with the RON protein,
one of the serial sections was incubated with a mixture of
anti-RON antibody and an excess molar ratio of antigen
peptide (Santa Cruz Biotechnology, Inc.), then processed as
described above.
IMMUNOPRECIPITATION AND WESTERN
BLOTTING
Each 300 ml sample of induced sputum obtained from
bronchiectasis subjects and from control subjects was
incubated for 6 h at 48C with protein G-Sepharose
(Pharmacia, Uppsala, Sweden) precoated with a mouse
monoclonal anti-human MSP antibody (MSP89-2S, Amer-
ican Type Culture Collection HB-10522, Rockville, MD)
with an equal volume of 26Triton lysis buer [100 mM
Hepes, pH 7?4, 2% Triton X-100, 300 mM NaCl, 2 mM
EDTA and protease inhibitors (50 mg ml71 aprotinin, 1 mM
PMSF, 100 mM leupeptin, 25 mM pepstatin A)]. Immune
complexes were collected on protein G-Sepharose. Immu-
noprecipitates were boiled for 3 min at 1008C in sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buer with 5% 2-mercaptoethanol (2-ME),
then resolved by SDS-PAGE using 10% polyacrylamide as
described by Laemmli (19). Recombinant human pro-MSP
and MSP (Toyobo Co., Shiga, Japan) were also applied to
the gel for reference markers. After electrophoresis,
proteins were transferred onto a PVDF membrane (Nihon
Millipore Ltd, Yonezawa, Japan). The a-chain of mature
MSP and pro-MSP were evaluated with a rabbit polyclonal
anti-human MSP antibody (Toyobo Co.). Specific binding
was detected using the enhanced chemiluminescence (ECL)
detection system (Amersham International).
TABLE 1. Characteristics of study population
Subjects Sex Age
(years)
Smoking
(pack-years)
FVC
(%pred)
FEV1/FVC
(%)
Bacteria
in sputum
Patients with bronchiectasis
1 F 47 0 70?8 94?8 Normal flora
2 F 67 0 82?6 77?6 H. influenzae
3 M 57 25 92?2 89?3 P. aeruginosa
4 M 46 50 61?2 52?7 Normal flora
5 F 66 0 72?1 79?0 P. aeruginosa
6 F 62 0 79?0 75?0 Normal flora
7 M 63 0 134?0 89?1 Normal flora
8 M 71 0 127?7 58?6 H. influenzae
Mean 59?9 9?4 90?0 77?0
SEM 3?3 6?6 9?5 5?3
Normal controls
1 M 51 0 110?0 85?0 Normal flora
2 M 63 40 107?9 78?1 Normal flora
3 M 58 35 103?0 80?1 Normal flora
4 F 61 0 119?0 84?0 Normal flora
5 M 70 40 96?0 77?0 Normal flora
6 F 60 0 98?1 84?8 Normal flora
7 M 34 0 102?0 88?0 Normal flora
8 M 33 0 110?1 108?2 Normal flora
9 M 30 0 116?1 96?1 Normal flora
Mean 51?1 12?8 106?9 86?8
SEM 5?0 6?4 2?5 3?1
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INDUCED SPUTUM
MSP concentrations in serum and the supernatant of
induced sputum were measured by sandwich-type ELISA.
This ELISA system detects both MSP and pro-MSP.
Briefly, a microtitre plate was coated overnight at 48C with
a mouse monoclonal anti-human MSP antibody. After
blocking with 3% bovine serum albumin in PBS, the plate
was incubated with diluted standards or samples. After
washing, the plate was incubated with a rabbit polyclonal
anti-human MSP antibody, followed by HRP-conjugated
anti-rabbit IgG (Amersham International). Specific binding
was detected by incubating the plate with 0?05 M phos-
phate-citrate buer containing 0?4 mg ml71 o-phenylene-
diamine dihydrochloride and 0?4 mg ml71 urea hydrogen
peroxide (Sigma Chemical Co., ST. Louis, MO, U.S.A.).
The absorbance at 450 nm was measured in an automated
microplate reader (Molecular Devices Corp., Sunnyvale,
CA, U.S.A.). MSP concentrations were determined by
interpolation of thier absorbance from a standard curve.
STATISTICAL ANALYSIS
Results are shown as mean +SEM. The dierences between
groups were compared with Mann–Whitney’s U-tests. A
value of P50?05 was considered significant.Results
We studied eight patients with bronchiectasis and nine
control subjects. There was no significant dierence in FVC
(%pred) and FEV1/FVC (%) between the two groups.
Haemophilus influenzae was detected in two patients and
Pseudomonas aeruginosa was detected in another two
patients (Table 1).
To examine the expression of RON on the bronchial
ciliated epithelium, we performed immunohistochemical
staining of bronchial tissues obtained from normal control
and two patients with bronchiectasis using an anti-RON
antibody. The bronchial ciliated epithelium was clearly
stained with anti-RON in both normal control [Fig. 1(A)]
and two patients with bronchiectasis [Fig. 1(C,E)]. Notably,
the positive staining was localized at the apical surface of
the cells. In addition, the positive staining was also observed
in damaged ciliated epithelium as well as relatively intact
ciliated epithelium. The specific reactivity of anti-RON
antibody with RON was confirmed by the finding that
positive staining was completely blocked by an excess molar
ratio of antigen peptide [Fig. 1(B,D,F)]. Negative staining of
goblet cells in bronchial epithelium was confirmed by
comparing immunohistochemical staining with anti-RON
and PAS staining using serial sections (data not shown).
To test our prediction that MSP is present in sputum of
patients with bronchiectasis and normal control subjects,
we performed immunoprecipitations using induced sputum
samples from three bronchiectasis subjects and three
FIG. 1. Immunolocalization of RON in the bronchial ciliated epithelium of normal control and two patients with
bronchiectasis. (A) The apical surface of the normal bronchial ciliated epithelium showed positive staining (arrowheads). (B)
The positive staining was completely blocked in the presence of an excess molar ratio of antigen peptide (A,B6132). (C,E)
The apical surface of the bronchial ciliated epithelium obtained from bronchiectatic patients also showed positive staining
(arrowheads). Positive staining was also observed in damaged ciliated epithelium as well as relatively intact ciliated
epithelium. (D,F) The positive staining was completely blocked in the presence of an excess molar ratio of antigen peptide
(C-F6100).
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antibody. Western blotting with a rabbit polyclonal anti-
human MSP antibody that detects mature MSP and pro-
MSP showed that these sputa contain comparable levels ofMSP a-chain and pro-MSP (Fig. 2). These results indicate
that half of the MSP in sputum is present as biologically
active mature MSP in both patients with bronchiectasis and
normal controls.
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measured concentrations of MSP in serum and induced
sputum of patients with bronchiectasis and normal control
subjects. As shown in Table 2, serumMSP (pro-MSP) levels
were 7?8+0?5 mg ml71 in patients with bronchiectasis and
8?1+0?3 mg ml71 in normal controls. There was no
significant dierence between the two groups. On the other
hand, MSP levels in induced sputum were 16?8+3?0 ng
ml71 in patients with bronchiectasis and 8?4+2?4 ng ml71
in normal controls (P50?05). Thus, MSP levels were
significantly increased in sputum but not in the serum of
patients with bronchiectasis as compared with normal
controls.
Discussion
It has been recognized that the eectiveness of MCC
depends on three factors: ciliary function, secretion of
mucins and other macromolecules, and fluid secretion. In
particular, ciliary function and interaction between cilia
and mucus have been shown to be critical for airway
mucociliary transport (5). In our recent study, we showed
that the MSP-RON signalling pathway functions as one
regulatory system of ciliary motility in vitro (9); however,
the significance of this pathway in the airway mucociliary
transport in vivo remains to be elucidated.
In this study, we confirmed that RON is also expressed at
the apical surface of bronchial ciliated epithelium of
patients with bronchiectasis as well as those of normal
human bronchus. In addition, we confirmed that MSP is
present in the sputum of patients with bronchiectasis and
normal control subjects, and that half of the MSP inFIG. 2. Detection by Western blotting of MSP a-chain and
pro-MSP in induced sputum. Each sputum from three
bronchiectasis subjects (BE 1–BE 3) and three control
subjects (NC 1–NC 3) was immunoprecipitated with
mouse monoclonal anti-MSP. Immunoprecipitates were
Western blotted with rabbit polyclonal anti-MSP. Pure
pro-MSP and MSP standards were run in the first two
lanes. The six sputum lanes all show MSP a-chain and
pro-MSP bands. MSP concentrations in sputum in each
case were as follows; BE 1: 26?0 ng ml71, BE 2:
18?3 ng ml71 BE 3: 17?4 ng ml71, NC 1: 7?0 ng ml71, NC
2: 6?4 ng ml71, NC 3: 2?7 ng ml71.sputum is present as a biologically active a/b chain
heterodimer (mature MSP). Previous studies have shown
that MSP is produced by hepatocytes (11,13,15) and
secreted into the circulation as biologically inactive pro-
MSP, the single-chain precursor of MSP, and maintained in
serum as pro-MSP (20). Furthermore, pro-MSP has been
shown to be cleaved to a biologically active a/b chain
heterodimer by serum kallikrein and coagulation Factors
XIIa and XIa in vitro (16). Our results suggest that MSP is
supplied to the airways from the circulation and converted
to an active form. Taken together with the finding that the
MSP receptor, RON, is localized to the apical surface of
airway ciliated epithelium, it seems reasonable to conclude
that MSP in sputum binds to and activates RON on the
airway ciliated epithelium resulting in stimulation of ciliary
motility in vivo.
Wang et al. previously showed that resident murine
peritoneal macrophages, one of the target cells for MSP,
have enzymatic activities that proteolytically cleave pro-
MSP (20). These results suggest that control of MSP
activity can occur at the level of the target cell by
proteolytic cleavage of pro-MSP to mature MSP. Since
the mechanism of proteolytic cleavage of serum pro-MSP
to mature MSP in sputum remains to be clarified, it will be
of interest to explore whether airway ciliated epithelial cells,
one of the target cells for MSP, contain enzymatic activity
that proteolytically cleaves pro-MSP to mature MSP.
The Haemophilus influenzae and Pseudomonas aeruginosa
frequently colonize in the respiratory tract of patients with
bronchiectasis (6), and these bacterial and inflammatory
cell products have been shown to have a detrimental eect
on the mucociliary transport apparatus. For example,
soluble products of Haemophilus influenzae and Pseudomo-
nas aeruginosa can decrease CBF (21,22); pyocyanin, 1-
hydroxyphenazine and rhamnolipids were found to be the
putative agents in Pseudomonas aeruginosa (7,23,24).
Furthermore, the following inflammatory mediators re-
leased into the airway lumen during inflammation have
been shown to decrease CBF: hydrogen peroxide (25),
human neutrophil elastase (26) and neutral protease (27).
Thus, the eect of these bacterial products and inflamma-
tory mediators in vivo is cilioinhibition, and this inhibitionTABLE 2. MSP concentrations in serum and induced sputum
MSP concentrations
Subjects Number Serum
(mg ml71)
Induced
sputum
(ng ml71)
Bronchiectasis 8 7?8+0?5 16?8+3?0*
Normal controls 9 8?1+0?3 8?4+2?4
Values are presented as mean +SEM.
*P50?05 compared with normal controls.
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bronchiectasis.
On the contrary, a number of mediators have been shown
to increase CBF in vitro and in vivo (5), however, the
involvement of these mediators in bronchiectasis is not fully
examined. In the present study, the concentrations of MSP
in sputum were significantly elevated in patients with
bronchiectasis compared with normal controls. On the
other hand, the concentrations of serum MSP (pro-MSP)
were similar in the two groups. These findings indicate that
biologically active mature MSP is significantly increased in
the airways but not in the serum of patients with
bronchiectasis. The high concentrations of MSP in sputum
of patients with bronchiectasis may be caused by the
increase in transudation of serum pro-MSP during the
inflammatory process. Thus, MSP may play a compensa-
tory role in MCC of patients with bronchiectasis.
An increase in CBF usually translates into an increased
MCC, yet MCC has been depressed in bronchiectasis. It is
possible that, despite the stimulatory eect of MSP on
ciliary motility, abnormal load and rheology of mucus
predominantly contribute to the impairment of MCC in
bronchiectasis (28). Moreover, since ciliated epithelia of
patients with bronchiectasis are damaged and accompanied
by loss of epithelial ciliation due to ciliotoxic bacterial
products and inflammatory mediators (26), those may not
eectively respond to MSP. At present both the mechanism
of MSP activation in vivo and control of its concentration in
the airways are under investigation.
In conclusion, we have shown that MSP is present in
sputum as biologically active mature MSP and significantly
increased in sputum of patients with bronchiectasis. In the
MCC of patients with bronchiectasis, MSP might act as a
ciliary activity factor to compensate for impaired MCC.
Acknowledgements
We are grateful to Dr T. Takehara for kindly providing
recombinant human pro-MSP and MSP and N. Yamaguchi
for helpful discussion.
References
1. Barker AF, Bardana EJ, Jr. Bronchiectasis: update of
an orphan disease. Am Rev Respir Dis 1998; 137: 969–
978.
2. Fahy JV, Schuster A, Ueki I, Boushey HA, Nadel JA.
Mucus hypersecretion in bronchiectasis: the role of
neutrophil proteases. Am Rev Respir Dis 1992; 146:
1430–1433.
3. Lourenco RV, Loddenkemper R, Carton RW. Patterns
of distribution and clearance of aerosols in patients
with bronchiectasis. Am Rev Respir Dis 1972; 106: 857–
866.
4. Currie DC, Pavia D, Agnew JE, et al. Impaired
tracheobronchial clearance in bronchiectasis. Thorax
1987; 42: 126–130.5. Wanner A, Salathe´ M, O’riordan TG. Mucociliary
clearnace in the airways. Am J Respir Crit Care Med
1996; 154: 1868–1902.
6. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter
R. Clinical, pathophysiologic, and microbiologic char-
acterization of bronchiectasis in an aging cohort. Chest
1995; 108: 955–961.
7. Wilson R, Pitt T, Taylor G, et al. Pyocyanin and 1-
hydroxyphenazine produced by Pseudomonas aerugi-
nosa inhibit the beating of human respiratory cilia in
vitro. J Clin Invest 1987; 79: 221–229.
8. Munro NC, Barker A, Rutman A, et al. Eect of
pyocyanin and 1-hydroxyphenazine on in vivo tracheal
mucus velocity. J Appl Physiol 1989; 67: 316–323.
9. Sakamoto O, Iwama A, Amitani R, et al. Role of
macrophage-stimulating protein and its receptor, RON
tyrosine kinase, in ciliary motility. J Clin Invest 1997;
99: 701–709.
10. Leonard EJ, Skeel A. A serum protein that stimulates
macrophage movement, chemotaxis and spreading.
Exp Cell Res 1976; 102: 434–438.
11. Han S, Stuart LA, Degen SJF. Characterization of the
DNF15S2 locus on human chromosome 3: identifica-
tion of a gene coding for four kringle domains with
homology to hepatocyte growth factor. Biochemistry
1991; 30: 9768–9780.
12. Skeel A, Yoshimura T, Showalter SD, Tanaka S,
Appella E, Leonard EJ. Macrophage stimulating
protein: purification, partical amino acid sequence,
and cellular activity. J Exp Med 1991; 173: 1227–1234.
13. Yoshimura T, Yuhki N, Wang M-H, Skeel A, Leonard
EJ. Cloning, sequencing, and expression of human
macrophage stimulating protein (MSP, MST1) con-
firms MSP as a member of the family of kringle
proteins and locates the MSP gene on chromosome 3. J
Biol Chem 1993; 268: 15461–15468.
14. Shimamoto A, Kimura T, Matsumoto K, Nakamura
T. Hepatocyte growth factor-like protein is identical to
macrophage stimulating protein. FEBS Lett 1993; 333:
61–66.
15. Bezerra JA, Witte DP, Aronow BJ, Degen SJF.
Hepatocyte-specific expression of the mouse hepatocyte
growth factor-like protein.Hepatology 1993; 18: 394–399.
16. Wang M-H, Yoshimura T, Skeel A, Leonard EJ.
Proteolytic conversion of single chain precursor macro-
phage-stimulating protein to a biologically active
heterodimer by contact enzymes of the coagulation
cascade. J Biol Chem 1994; 269: 3436–3440.
17. Pin I, Gibson PG, Kolendowicz R, et al. Use of
induced sputum cell counts to investigate airway
inflammation in asthma. Thorax 1992; 47: 25–29.
18. Isobe Y, Chen S-T, Nakane PK, Brown WR. Studies
on translocation of immunoglobulins across intestinal
epithelium. I. Improvements in the peroxidase-labeled
antibody method for application to study of human
intestinal mucosa. Acta Histochem Cytochem 1997; 10:
161–171.
19. Laemmli UK. Cleavage of structural proteins during
assembly of the head of bacteriophage T4. Nature 1970;
227: 680–685.
790 Y. TAKANO ET AL.20. Wang M-H, Skeel A, Leonard EJ. Proteolytic cleavage
and activation of pro-macrophage stimulating protein
by resident peritoneal macrophage membrane pro-
teases. J Clin Invest 1996; 97: 720–727.
21. Wilson R, Roberts D, Cole P. Eect of bacterial
products on human ciliary function in vitro. Thorax
1985; 40: 125–131.
22. Wilson R, Cole PJ. The eect of bacterial products on
ciliary function. Am Rev Respir Dis 1988; 138: 49–53.
23. Wilson R, Sykes DA, Watson D, Rutman A, Taylor
GW, Cole PJ. Measurement of Pseudomnas aeruginosa
phenazine pigments in sputum and assessment of their
contribution to sputum sol toxicity for respiratory
epithelium. Infect Immun 1988; 56: 2515–2517.
24. Read RC, Roberts P, Munro N, et al. Eect of
Pseudomonas aeruginosa rhamnolipids on mucociliary
transport and ciliary beating. J Appl Physiol 1992; 72:
2271–2277.25. Kobayashi K, Salathe´ M, Pratt MM, et al. Mechanism
of hydrogen peroxide induced inhibition of sheep
airway cilia. Am J Respir Cell Mol Biol 1992; 6: 667–
673.
26. Amitani R, Wilson R, Rutman A, et al. Eects of
human neutrophil elastase and Pseudomnas aeruginosa
proteinases on human respiratory epithelium. Am J
Respir Cell Mol Biol 1991; 4: 26–32.
27. Tegner H, Ohlsson K, Toremalm NG, von Mecklen-
burg C. Eect of human leukocyte enzymes on tracheal
mucosa and its mucociliary activity. Rhinology 1979;
17: 199–206.
28. Wills PJ, Garcia Suarez MJ, Rutman A, Wilson R,
Cole PJ. The ciliary transportability of sputum is slow
on the mucus-depleted bovine trachea. Am J Respir
Crit Care Med 1995; 151: 1255–1258.
